Zura Bio Limited
Zura Bio Limited (94E.F) Stock Overview
Explore Zura Bio Limited’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
73M
P/E Ratio
-1.99
EPS (TTM)
$-0.67
ROE
-0.43%
94E.F Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Zura Bio Limited (94E.F) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 67.52, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.24.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.99 and a market capitalization of 73M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Company Profile
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.
Robert Lisicki
30
4225 Executive Square, San Diego, CA
2023